Innovative therapeutics firm Marinus Pharmaceuticals Inc. widened its net loss in the past year after recording a higher deficit in the last three months of the year, the company announced in a filing.
- Net loss for the fourth quarter of 2021 increased to $28.305 million from the $17.549 million recorded in the same quarter of 2020, bringing the diluted net loss per share to $0.77 from $0.55. Revenue fell to $1.520 million from $1.546 million.
- Full-year 2021 net loss stood at $98.776 million, higher than the $76.335-million loss the firm reported in 2020. The diluted net loss per share improved to $2.69 from $2.80, with revenue up to $15.345 million from $1.718 million.
- Marinus expects 2022 revenues between $7 million and $10 million, and total operating expenses inclusive of general and administrative and research and development costs between $152 million and $157 million.
The company said it can also avail an additional $30-million worth of funding under the existing credit agreement with Oaktree Capital Management LP. MRNS is down 4.90% premarket.